Posted by Michael Wonder on 10 Nov 2017
NICE recommends Mavenclad (cladribine tablets) for highly active multiple sclerosis
9 November 2017 - First multiple sclerosis therapy to achieve positive NICE recommendation in the shortest possible timeframe.
Merck today announced that NICE in the United Kingdom has issued a final appraisal determination recommending Cladribine Tablets (Mavenclad) as an option for treating highly active multiple sclerosis in adults.
Use of cladribine tablets is recommended only if the person has: rapidly evolving severe relapsing–remitting multiple sclerosis, that is, at least two relapses in the previous year and at least one T1 gadolinium-enhancing1 lesion at baseline MRI or relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity.
This decision comes only two months after the European Commission granted marketing authorisation for Mavenclad in August 2017.
